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Retinal Architecture in RGS9- and
R9AP-Associated Retinal Dysfunction
(Bradyopsia)
RUPERT W. STRAUSS, ADAM M. DUBIS, ROBERT F. COOPER, ROLA BA-ABBAD, ANTHONY T. MOORE,
ANDREW R. WEBSTER, ALFREDO DUBRA, JOSEPH CARROLL, AND MICHEL MICHAELIDES
 PURPOSE: To characterize photoreceptor structure and
mosaic integrity in subjects with RGS9- and R9AP-asso-
ciated retinal dysfunction (bradyopsia) and compare to
previous observations in other cone dysfunction disorders
such as oligocone trichromacy.
 DESIGN: Observational case series.
 METHODS: SETTING: Moorfields Eye Hospital (United
Kingdom) and Medical College Wisconsin (USA). STUDY
POPULATION: Six eyes of 3 subjects with disease-causing
variants in RGS9 or R9AP. MAIN OUTCOME MEASURES:
Detailed retinal imaging using spectral-domain optical
coherence tomography and confocal adaptive-optics scan-
ning light ophthalmoscopy.
 RESULTS: Cone density at 100 mm from foveal center
ranged from 123 132 cones/mm2 to 140 013 cones/
mm2. Cone density ranged from 30 573 to 34 876
cones/mm2 by 600 mm from center and from 15 987 to
16,253 cones/mm2 by 1400 mm from center, in keeping
with data from normal subjects. Adaptive-optics imaging
identified a small, focal hyporeflective lesion at the foveal
center in both eyes of the subject with RGS9-associated
disease, corresponding to a discrete outer retinal defect
also observed on spectral-domain optical coherence to-
mography; however, the photoreceptor mosaic remained
intact at all other observed eccentricities.
 CONCLUSIONS: Bradyopsia and oligocone trichromacy
share common clinical symptoms and cannot be discerned
on standard clinical findings alone. Adaptive-optics imag-
ing previously demonstrated a sparse mosaic of normal
wave-guiding cones remaining at the fovea, with no visible
structure outside the central fovea in oligocone trichro-
macy. In contrast, the subjects presented in this study
with molecularly confirmed bradyopsia had a relatively
intact and structurally normal photoreceptor mosaic,
allowing the distinction between these disorders based on
the cellular phenotype and suggesting different
pathomechanisms. (Am J Ophthalmol 2015;160(6):
1269–1275.  2015 The Authors. Published by
Elsevier Inc. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).)
T
HE PHENOMENON OF BRADYOPSIA (‘‘SLOW VISION’’:
OMIM 608415) was first described by Kooijman
and associates in 4 patients from 3 unrelated Dutch
families.1 Disease-causing sequence variants have been
identified in either RGS9 (encoding a GTPase-activating
protein) or R9AP (encoding its membrane anchor protein),
with both playing a critical role in the recovery phase of vi-
sual transduction.2,3
Bradyopsia (RGS9/R9AP-associated retinopathy) is
characterized by reduced central vision from childhood,
with mild photophobia, absence of nystagmus, normal co-
lor vision and night vision, and normal fundus appearance.
However, patients report slow visual adaptation to changes
in illumination, in both dark- and light-adapted states.3–5
These symptoms are shared with oligocone trichromacy,
another cone dysfunction syndrome characterized by
normal fundus appearance, normal or near-normal color
vision, reduced visual acuity from infancy, and mild photo-
phobia.5–7 Unlike RGS9/R9AP-associated retinopathy,
the underlying molecular genetic basis of oligocone
trichromacy remains uncertain. Oligocone trichromacy
and/or a ‘‘marked incomplete achromatopsia (ACHM)-
like’’ phenotype have been reported in association with
‘‘hypomorphic’’ mutations in the CNGA3, CNGB3,
PDE6C, andGNAT2 genes.5 However, some of these cases
arguably have features more in keeping with incomplete
achromatopsia per se, rather than oligocone trichromacy.5
Electroretinograms according to the protocol
recommendations by the International Society for
Clinical Electrophysiology of Vision (ISCEV)8,9 also
do not allow for the distinction to be made
between RGS9/R9AP-associated retinopathy and
oligocone trichromacy, with more comprehensive
electroretinograms than those mandated by the ISCEV in
the electroretinogram standard document being needed.
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Extended electroretinogram testing includes dark-adapted
red flash electroretinogram (which has both a cone and
rod system component) and dark-adapted 10.0 (or 11.5)
electroretinograms with a wider range of increasing inter-
stimulus intervals are necessary to establish the correct
diagnosis.3,10 However, both oligocone trichromacy and
RGS9/R9AP-associated retinopathy are associated with
generalized cone system dysfunction, with an
undetectable light-adapted 30 Hz flicker electroretinogram
and a severely reduced light-adapted 3.0 electroretinogram.
Recently, photoreceptor topography was assessed in 3
subjects with typical oligocone trichromacy, confirmed to
not harbor variants in either RGS9 or R9AP, using
adaptive-optics flood-illuminated ophthalmoscopy (AO-
Flood).11 These patients were all found to have a reduced
number of waveguiding cones at the fovea, with no struc-
ture visible outside the central fovea—thereby confirming
the original hypothesis of the underlying basis of oligocone
trichromacy, that the disorder was caused by a reduction in
number of otherwise functional cone photoreceptors.
In this study, we have undertaken deep phenotyping of
molecularly proven patients with either RGS9- or R9AP-
associated retinopathy. Spectral-domain optical coherence
tomography was used to both qualitatively and quantita-
tively examine retinal laminar integrity and confocal
adaptive-optics scanning light ophthalmoscopy was used
to directly probe photoreceptor mosaic architecture in or-
der to determine (1) whether oligocone trichromacy and
RGS9/R9AP-associated retinopathy could be discerned at
the cellular level, and (2) whether the generalized retinal
dysfunction in RGS9/R9AP-associated retinopathy is sec-
ondary to cone cell loss/structural deficit or a functional
deficit in otherwise intact receptors.
SUBJECTS AND METHODS
 SUBJECTS: This observational case series was conducted
in accordance with the tenets of the Declaration of
Helsinki (1983 Revision) and the applicable regulatory re-
quirements, and in compliance with the Health Insurance
Portability and Accountability Act (HIPAA). After
approval of the study and its procedures by the local ethics
committees of Moorfields Eye Hospital and the Medical
College of Wisconsin, informed consent was obtained
from all participating subjects prior to enrollment.
All 3 subjects have been previously reported: subjects
MM_0032, MM_0033, and JC_0759 correspond to cases
1A, 2A, and 3, respectively, in the series published by
Michaelides and associates.3 The Table summarizes clinical
findings and subject demographics. All subjects had the
pathognomonic electroretinogram findings associated with
bradyopsia as described previously3: In brief, the dark-
adapted 0.01 electroretinogram (rod electroretinogram),
the dark-adapted red flash electroretinogram (which has
both a cone and rod system component), and the dark-
adapted 3.0 electroretinogram (combined rod-cone standard
flash electroretinogram; rod dominated given numerosity)
with interstimulus interval of 2 minutes were all normal.
However, with an interstimulus interval of 20 seconds, ampli-
tude reduction was observed in DA 11.5 electroretinograms,
which was progressively less marked with increasing inter-
stimulus interval, consistent with delayed recovery after the
flash. Light-adapted testing revealed an undetectable pattern
electroretinogram and 30 Hz flicker electroretinogram.
Pupils of each patient were dilated using 1 drop each of
phenylephrine (2.5%) and tropicamide (1%) before imag-
ing in the study herein.
 SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRA-
PHY: All subjects underwent spectral-domain optical
coherence tomography using an Envisu C2300 system (Bio-
ptigen, Morrisville, North Carolina, USA) through the
macular region. Macular scans, either 750 A-scans/B-scan
and 150 B-scans or 1000 A-scans/B-scan and 100 B-scans,
over a nominally 73 7mm area were acquired to locate the
center of the fovea. Then, high-density line scans were ac-
quired (1000 A-scans/B-scan), and ImageJ (NIH,
Bethesda, Maryland, USA) was used to register up to 100
B-scans and average them to reduce speckle noise.11 To
correct for retinal magnification, axial length was measured
in all subjects (Zeiss IOL Master; Carl Zeiss Meditec,
Dublin, California, USA) in order to estimate the lateral
scale of each image and to correct the interindividual dif-
ferences.12 In order to analyze the retinal cross-section
and determine total retinal thickness, inner retinal thick-
ness, and outer nuclear layer thickness, foveal scans were
TABLE. Demographics and Clinical Findings for 3 Subjects With Genetically Confirmed Bradyopsia
Subject Number Age (y) Sex
Visual Acuity Axial Length (mm)
Gene Allele 1 / Allele 2 AOSLO UsedOD OS OD OS
JC_0759 62 M 6/12 6/12 23.16 22.92 RGS9 p.W299R / p.R128X MCW
MM_0032 25 F 6/12 6/12 30.36 27.84 R9AP p.D32_Q34del / p.D32_Q34del MEH
MM_0033 16 F 6/18 6/12 24.98 24.84 R9AP p.D32_Q34del / p.D32_Q34del MEH
AOSLO ¼ adaptive-optics scanning light ophthalmoscope; MCW ¼ Medical College of Wisconsin; MEH ¼ Moorfields Eye Hospital.
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manually segmented using ImageJ (NIH) and a Matlab
(MATLAB; MathWorks, Natick, Massachusetts, USA)-
based algorithm.13,14
The following definitions were applied: total retinal
thickness was defined as the distance from the inner
limiting membrane to the retinal pigment epithelium; in-
ner retinal thickness as the distance from the inner limiting
membrane to the outer plexiform layer; and outer nuclear
layer thickness as the distance from the outer plexiform
layer to the external limiting membrane. Layer designa-
tions are shown in Figure 1 (Top left). Thicknesses were
compared to those derived from a normative database
collected at Medical College Wisconsin, consisting of
167 normal individuals (72 male, 95 female, average age
of 32.6 years [range 7-60 years]).13,15
 CONFOCAL ADAPTIVE-OPTICS RETINAL IMAGING: Im-
ages of the photoreceptor mosaic were obtained using 1
of 2 nearly identical adaptive-optics scanning light oph-
thalmoscopes located at Medical College Wisconsin and
Moorfields Eye Hospital.16,17 The difference between the
systems was the center wavelength of the imaging source.
The imaging source at Moorfields Eye Hospital was a
790 nm superluminescent diode (Superlum Ireland,
Carrigtwohill, County Cork, Ireland) while the imaging
source at Medical College Wisconsin was a 775 nm
superluminescent diode (Inphenix Inc, Livermore,
California, USA). Both systems operated at w17 frames/
second. Wavefront aberrations were corrected using a 97-
actuator deformable mirror (ALPAO, Biviers, France). Im-
age sequences were recorded at different locations across
the central fovea and parafovea. Each image sequence
was desinusoided and registered using algorithms described
by Dubra and associates.18 The resultant image from each
sequence was then manually combined into a large
montage (Adobe Photoshop; Adobe Systems, Inc, San
Jose, California, USA). Each subject’s axial length was
used to determine the absolute scale of his or her retinal im-
ages, ensuring the accuracy of subsequent measurements of
the cone mosaic.
FIGURE 1. Spectral-domain optical coherence tomography B-scans in 3 subjects with bradyopsia. Top left: A representative macular
line scan is shown with designated layer thickness measurements. Bottom left: Total retinal thickness was normal in all subjects
compared to a normative database. Normative average thickness is shown as a black line ± 2 standard deviations (gray shaded region).
Inner retinal thickness (Top right) and outer nuclear layer thickness (Bottom right) was within the normal range for all subjects
compared to a normative database. Subject JC_0759 is represented by a triangle, MM_0032 as a square, and MM_0033 as a circle
throughout.
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From these images, cone density measurements were ob-
tained using aMatlab-aided direct counting procedure.12,13
Cone photoreceptors were identified within an 803 80mm
region of interest at the location of peak cone density (0)
when possible, and at 100, 200, 300, 400, 600, 800, 1000,
1200, and 1400 mm temporal eccentricity. Cone density
was then calculated over the central 55 3 55 mm area to
mitigate the effect of edge artifacts.19 Cone densities
were compared to normal data published by Curcio and as-
sociates.20 Owing to the focal foveal lesion present in
JC_0759, the center of the lesion was assumed to be the
location of peak cone density, and all measurements were
based from this location.
RESULTS
 SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRA-
PHY: Volumetric and foveal spectral-domain optical
coherence tomography images were obtained in both eyes
of all subjects. Foveal scans from all subjects are shown in
Figure 2. Qualitative assessment of the inner segment ellip-
soid band showed that JC_0759 had focal foveal disruption
of the inner segment ellipsoid band in both eyes, while
there was normal macular lamination in both eyes of
MM_0032 and MM_0033 (Figure 2). Total, inner retinal,
and outer nuclear layer thickness was within 2 standard de-
viations of normal for all subjects (Figure 1).
 QUALITATIVE ASSESSMENT OF THE PHOTORECEPTOR
MOSAIC: Adaptive-optics scanning light ophthalmoscopy
imaging identified a small focal central hyporeflective lesion
(nonwaveguiding cones) in both eyes of JC_0759. The
lesion was present at the foveal center; however, cone
mosaic integrity was intact at all other observed eccentric-
ities. A foveal montage for subject JC_0759’s right eye is
shown in Figure 3. Subjects MM_0032 and MM_0033
had qualitatively normal waveguiding cone photoreceptors
at all imaged locations. The foveal montage for subject
MM_0033’s right eye is shown in Figure 3. Selected location
photoreceptor images are shown in Figure 4. Consistent
with the focal lesion in JC_0759, no photoreceptors are
visible at the center using confocal adaptive-optics scan-
ning light ophthalmoscopy. Cone photoreceptors are
visible (roughly equally sized circular objects) in the images
from peak density until 400 mm from the center.
 QUANTITATIVE ASSESSMENT OF CONE PHOTORE-
CEPTOR DENSITY: Measured cone densities were within
the normal range reported in histologic analysis at all 10 lo-
cations in both eyes of subjects MM_0032 and MM_0033.20
The aforementioned foveal defect in patient JC_0759 was
reflected by a decreased cell number at the area of expected
peak cone density. Cone density at 100 mm from center, the
FIGURE 2. Horizontal spectral-domain optical coherence to-
mography images through the fovea of all 3 bradyopsia subjects.
Qualitative spectral-domain optical coherence tomography anal-
ysis shows a focal disruption in the inner segment ellipsoid and
interdigitation zone in JC_0759 (Top). This contrasts to the
intact outer retinal lamination present in MM_0032 (Middle)
and MM_0033 (Bottom). The arrows on JC_0759 and
MM_0033 indicate the location of the adaptive-optics scanning
light ophthalmoscopy montage shown in Figure 3.
FIGURE 3. Foveal montages derived from adaptive-optics scan-
ning light ophthalmoscopy for the RGS9 subject JC_0759 and
R9AP subject MM_0033. The foveal montage for JC_0759
(Top) shows a hyporeflective lesion that corresponds to the
disruption seen on spectral-domain optical coherence tomogra-
phy in Figure 2. Conversely, the foveal montage from
MM_0033 (Bottom) shows a qualitatively normal cone mosaic
across the foveal region. Scale bar is 100 mm.
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location closest to center measureable for all 3 subjects,
ranged from 123 132 to 140 013 cones/mm2. Cone density
ranged from 30 573 to 34 876 cones/mm2 by 600 mm from
center and 15 987 to 16 253 cones/mm2 by 1400 mm. These
cone densities at different locations are entirely in keeping
with both published histologic and in vivo image anal-
ysis.20–22 Quantification of cone photoreceptor density at
all measured eccentricities is shown in Figure 5.
DISCUSSION
OLIGOCONE TRICHROMACY AND RGS9/R9AP-ASSOCIATED
retinopathy share clinical characteristics including station-
ary cone dysfunction, mild photophobia, normal color
vision, and normal fundi. RGS9/R9AP-associated retinop-
athy can be distinguished from oligocone trichromacy on
the basis of molecular screening and distinct electrophysi-
ologic findings following extended assessment.3,5,10 We
conducted this study to characterize the retinal
architecture in RGS9/R9AP-associated retinopathy and
thereby shed light into any structural differences between
oligocone trichromacy and RGS9/R9AP-associated
retinopathy. We hypothesized that they could be
discerned on the basis of their cellular phenotype.
In a previous study in oligocone trichromacy, cone
photoreceptor imaging identified 2 types of subject. In 3
(out of 4) subjects, representing typical oligocone trichro-
macy, a uniform reduction in cone density was identified,
in combination with a reduced outer nuclear layer thick-
ness on spectral-domain optical coherence tomography;
these findings support the original hypothesis that oligo-
cone trichromacy is characterized by a reduced number of
functional cones.11 The findings of our present study in
RGS9/R9AP-associated retinopathy are in direct contrast,
providing evidence that cones are present in normal
numbers but are dysfunctional (Figure 6). This is in keeping
with the normal cone density identified histopathologically
in RGS9-knockout mice.23
Adaptive-optics scanning light ophthalmoscopy imaging
revealed a small focal hyporeflective lesion in both eyes at
the foveal center in the subject with RGS9-associated reti-
nopathy, which also correlated with a decreased cell num-
ber at this location, as well as bilateral focal interruption
of the interdigitation zone and inner segment ellipsoid
FIGURE 4. Photoreceptor images from multiple eccentricities obtained with adaptive-optics scanning light ophthalmoscopy in 2
bradyopsia patients. Photoreceptor images are shown at the center of peak density (lesion: JC_0759, Top row, and MM_0033, Bot-
tom row), and 200, 400, 800, and 1200 mm away from center of peak density. Cone photoreceptors were readily identifiable at all
locations except the center of JC_0759. Scale bar is 20 mm.
FIGURE 5. Cone photoreceptor density in relation to eccentric-
ity in 3 subjects with bradyopsia.Normal cone density established
by histologic analysis (Curcio and associates20) is shown as the
gray shaded region. Subject JC_0759 is represented by a triangle,
MM_0032 as a square, and MM_0033 as a circle. The 3 subjects
with bradyopsia have very similar cone densities from 0.3 mm
from peak density and thereby their respective symbols overlap.
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bands on spectral-domain optical coherence tomography.
There are at least 3 possible explanations for these struc-
tural changes: (1) they may be directly associated with
the RGS9 genotype; (2) they may be age related (indicative
of progression), given that the subject withRGS9 variants is
significantly older than theR9AP subjects; and (3) since the
RGS9 subject also reported repeated blunt trauma to both
eyes in the past, the possibility of an unrelated comorbidity
cannot be entirely ruled out, especially given previous re-
ports of subclincial photoreceptor disruption in response
to trauma.24,25 High-resolution imaging of further molecu-
larly proven patients, perhaps using newer nonconfocal im-
aging,26 will help to clarify the underlying cause of the outer
lamellar defect and photoreceptor mosaic disruption.
Both RGS9 and R9AP play critical roles in enabling
the rapid recovery of the phototransduction cascade.3
RGS9 significantly accelerates the hydrolysis of a-transdu-
cin bound guanosine-59-triphosphate to guanosine diphos-
phate, with lack of RGS9 leading to a substantial delay in
the recovery from light response in knockout mice.2,27
Similar observations have been made in the absence of
R9AP, which serves as an anchor protein for RGS9 to the
photoreceptor outer segment membrane and enhances
its activity by up to 70-fold.2,28 This delayed recovery
phase is reflected in subjects with RGS9/R9AP-associated
retinopathy by electrophysiologic assessment; with the
dark-adapted 10.0 (or 11.5) electroretinograms with ISCEV
standard interstimulus interval of 20 seconds showing ampli-
tude reduction, which is progressively less severe with
increasing interstimulus interval, consistent with delayed re-
covery following the flash, thereby demonstrating the need
for an extended interstimulus interval to obtain full recovery
of the electroretinogram following the previous flash.3,10
In RGS9/R9AP-associated retinopathy subjects, the
dark-adapted 0.01 electroretinogram (rod electroretino-
gram), the dark-adapted red flash electroretinogram (both
an early cone and later rod system component), and the
dark-adapted 3.0 electroretinogram (combined rod-cone
standard flash electroretinogram; rod dominated given
numerosity) with interstimulus interval of 2 minutes are
all normal—all in keeping with the relatively intact cone
and rod photoreceptor mosaic observed in our study. How-
ever, with light-adapted testing, a generalized reduction or
absence of cone responses is observed (pattern electroreti-
nogram, light-adapted 30 Hz flicker and light-adapted 3.0
electroretinograms). This may at first sight appear to be
incongruous with structural observations. However, afore-
mentioned electroretinograms to a red flash under dark
adaptation, which in a normal subject gives an early cone
system–derived response and a later rod system–derived
response, are completely normal, showing that dark-
adapted cones function normally, at least initially. Indeed,
even dark-adapted 30 Hz flicker responses (albeit to a dim
flash, with a short presentation time) are normal initially,
but become undetectable after approximately 10 seconds
of stimulation.3,10
These observations thereby are all in keeping with our
findings that cones are not only present in normal density,
but also capable of normal function, and thus potentially
amenable to rescue. While patients with either RGS9/
R9AP-associated retinopathy or oligocone trichromacy
have very similar clinical phenotypes, we highlight the
utility of cellular imaging in both effectively distinguishing
between these conditions and determining the potential
for therapeutic intervention. Adaptive-optics scanning
light ophthalmoscopy will be valuable to assess whether
RGS9/R9AP-associated retinopathy is indeed an entirely
stationary condition, given our findings in the RGS9 sub-
ject and the increasing evidence of progression in the
cone dysfunction syndromes.5,14
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